Introduction
Cytochrome P450 (P450) enzymes represent a family of phase I enzymes responsible for the metabolism of drugs and other xenobiotics (Nelson et al., 1996) . Changes in the activity of P450 enzymes cause pharmacokinetic drug-drug interactions (DDIs). In general, DDIs are the result of inhibition of P450-mediated metabolism. Therefore, it is very important to identify P450 isoforms responsible for drug metabolism in order to predict interaction potential with P450 inhibitor drugs. P450 reaction phenotyping is routinely performed with this aim during the early drug discovery (White, 2000) , and the process often yields candidates less likely to undergo drug-drug interactions (Suzuki et al., 2002) .
One method of P450 reaction phenotyping involves the incubation of P450-isoform selective chemical inhibitors with human liver microsomes (HLM) (Williams et al., 2003) .
The P450-isoform selective inhibitors available are furafylline for CYP1A2, 3-((pyridine-3-yl)-1H-pyrazol-5-yl)methanamine for CYP2A6, thiotepa for CYP2B6, montelukast for CYP2C8, sulfaphenazole for CYP2C9, S-benzylnirvanol for CYP2C19, quinidine for CYP2D6, 4-methylpyrazole for CYP2E1, and ketoconazole for CYP3A (Khojasteh et al., 2011) (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Drug InteractionsLabeling/ucm093664.htm#cypEnzymes). CYP2J2 is known for its role in metabolizing arachidonic acid to epoxyeicosatrienoic acids, which play significant roles in maintaining the homeostasis of the kidney, heart, and lung by controlling biological processes such as vasodialatory, anti-inflammatory and antioxidative effect (Node et al., 2001; Kroetz and Zeldin, 2002; Spector et al., 2004; Spiecker and Liao, 2005) . Recent researche has uncovered roles for cytochrome P450 2J2 (CYP2J2) in the metabolism of some drugs.
CYP2J2 plays a major role in the metabolic clearance of albendazole (Wu et al., 2013b) , amiodarone (Karkhanis et al., 2016) , astemizole (Matsumoto and Yamazoe, 2001) , ebastine (Liu et al., 2006) , and terfenadine (Lafite et al., 2006) . To date, little data are available on strong selective CYP2J2 inhibitors. Danazol (Lee et al., 2012; Lee et al., 2015) , hydroxyebastine (Yoon and Liu, 2011; Lee et al., 2015) , and telmisartan (Ren et al., 2013; Lee et al., 2015) have been reported as possessing strong inhibitory action, but their potential against CYP2J2 activity has been evaluated primarily using the recombinant CYP2J2 isoform instead of HLMs. In addition, they showed inhibitory action against other P450 isoforms. For
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This article has not been copyedited and formatted. The final version may differ from this version. (Lee et al., 2012) , while hydroxyebastine inhibited CYP2C9, CYP2C19, and CYP2D6 with K i values of 2.74, 10.2, and 3.83 µM, respectively (Yoon and Liu, 2011) . Telmisartan inhibited CYP2C9-mediated tolbutamide hydroxylase activity with an IC 50 value of 4.78 µM (Ren et al., 2013) . The inhibitory potential of danazol and telmisartan was not evaluated for the enzymes CYP2A6, CYP2B6, and CYP2E1.
In previous research, we screened fifty natural products obtained from medicinal plants for their inhibitory potential against CYP2J2 (Lee et al., 2014b) . Decursin showed moderate inhibitory action against CYP2J2-mediated astemizole O-demethylase activity with a K i value of 8.34 µM. We synthesized four decursin derivatives ( Fig. 1 ) and evaluated the inhibitory potential against CYP2J2 in order to discover a more potent CYP2J2 inhibitor. In addition, we evaluated their inhibitory potency against the action of nine other P450 isoforms in order to determine their selectivity for CYP2J2. The availability of a selective inhibitor for CYP2J2 would be greatly beneficial in assessing the extent of CYP2J2 contribution in drug metabolism. 8, . The mixture of 4-nitrocinnamic acid (1.2 Eq), 4, 160.4, 155.9, 153.7, 148.2, 144.2, 142.9, 140.3, 129.7, 129.7, 123.9, 122.0, 115.8, 112.9, 112.7, 103.6, 76.7, 70 . 8, . LKY-021 was prepared from cinnamic acid using the same procedure for LKY-047. 4, 160.8, 157.1, 155.0, 146.1, 144.2, 135.0, 131.3, 130.2, 130.2, 129.7, 129.7, 129.1, 118.4, 116.7, 113.8, 113.7, 104.5, 77.5, 70.8, 28.2, 25.0, 23.6 ; IT-TOF/MS: m/z = 399.1186
Materials and Methods

Chemicals
(7S)-(+)-(4-Nitro-phenyl)-acrylic acid,N-(3-dimethylaminopropyl)-N′-
(7S)-(+)-3-
[M+Na] + . , 8, . LKY-024 was prepared from 4-methoxycinnamic acid using the same procedure for LKY-047. Yield 91.2 %, white solid. mp:
(7S)-(+)-3-(4-Methoxy-phenyl)-acrylic acid
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This article has not been copyedited and formatted. The final version may differ from this version. 7, 162.6, 160.8, 157.2, 155.0, 145.9, 144.2, 130.8, 130.8, 130.2, 127.6, 116.8, 115.6, 115.1, 115.1, 113.8, 113.7, 104.5, 77.5, 70.6, 55.7, 28.3, 25.0, 23.5 ; IT-TOF/MS: 8, . LKY-046 was prepared from 4-bromocinnamic acid using the same procedure for LKY-047. 153.7, 144.2, 144.2, 133.2, 131.9, 130.6, 129.7, 124.1, 118.5, 115.8, 112.8, 112.7, 103.6, 76.7, 69.8, 27.1, 24.3, 23 µL ice-cold acetonitrile containing 100 nM of MBZ into the mixtures. Subsequent to mixing followed by centrifugation at 14,000 g for 5 min at 4°C, aliquots (1 µL) of the supernatant were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously (Yoon and Liu, 2011) .
Terfenadine Hydroxylase Assay. HLMs (0.25 mg/mL) containing terfenadine (0.2 µM)
were pre-incubated in the presence of inhibitor (0.2 -10 µM) for 5 min at 37°C. dextromethorphan, 50 µM for chlorzoxazone, and 5 µM for midazolam. Following a 15 min incubation period in HLMs (0.25 mg/mL) in the presence or absence of the inhibitor compound, the reaction was terminated and the mixtures centrifuged. Aliquots of the supernatants were analyzed by LC-MS/MS as described previously (Kim et al., 2005; Joo and Liu, 2013) , with some modifications.
Data Analysis. The IC 50 values were determined using the WinNonlin software (Pharsight, Mountain View, CA). The apparent kinetic parameters for inhibitory activity (K i ) were first estimated by graphical methods, such as Lineweaver-Burk, Dixon, and secondary reciprocal plots, and were more accurately determined by non-linear least squares regression analysis, based on the best enzyme inhibition model (Harold, 1976) using the WinNonlin software. In our experiments, the inhibition data were well fitted by the competitive inhibition model. The models tested included pure and partial competitive inhibition, noncompetitive inhibition, uncompetitive inhibition, and mixed-type inhibition.
Results and Discussion
Several studies conducted in recent years have reported a variety of potent and selective CYP2J2 inhibitors. Telmisartan and flunarizine with K i values of 0.42 and 0.94 µM, respectively could be used as moderately selective CYP2J2 inhibitors, but both compounds also inhibit CYP2C9 and CYP2D6 with IC 50 values of 4.78 and 7.89 µM, respectively (Ren et al., 2013) , therefore only demonstrating over 10-fold selectivity when evaluated against ive major P450 isoforms (CYP1A2, 2C9, 2C19, 2D6, and 3A). Danazol also showed no more than 15-fold selectivity for CYP2J2 when tested against these five P450 isoforms, although it noncompetitively inhibited CYP2J2-mediated astemizole O-demethylation activity (IC 50 = 0.07 µM) . Additionally, the selectivity measured did not take into consideration other minor but important P450 isoforms such as CYP2A6, CYP2B6, CYP2C8, and CYP2E1. To our knowledge, no highly selective CYP2J2 inhibitors that can be used in reaction phenotyping have yet been described.
In this study, the inhibitory effects of four decursin derivatives (LKY-021, -024, -046, and -047) on CYP2J2-mediated astemizole O-demethylase activity were evaluated in HLMs (Table 1) . LKY-047, the p-nitrobenzyl derivative of decursin, showed greater inhibitory potency against CYP2J2 activity than all the other compounds tested (IC 50 = 1.7 µM). The inhibition potency of LKY-047 was also higher than that of decursin (IC 50 = 6.95 µM) (Lee et al., 2014b) . LKY-024 (p-methoxybenzyl derivative) and -046 (p-bromobenzyl derivative)
showed weak inhibitory action against CYP2J2 activity with IC 50 values of 27.2 and 47.1 µM, respectively, whereas LKY-021 (benzyl derivative) had no inhibitory effect at all (IC 50 > 50 µM).
We further studied LKY-047 in order to clarify its inhibition mechanism. LKY-047 inhibited CYP2J2-mediated AST O-demethylase and terfenadine hydroxylase activities with K i values of 0.96±0.12 and 2.61±0.28 µM, respectively (Fig. 2) . The Lineweaver-Burk plots intersected on the y-axis (Harold, 1976; Waldrop, 2009) , indicating that LKY-047 competitively inhibited the enzyme activities of both astemizole ( Fig Danazol ) and telmisartan (Ren et al., 2013) showed 15-and 10-fold selectivity for CYP2J2 inhibition respectively. To evaluate the selectivity of the tested inhibitors for CYP2J2, we examined the inhibitory activities of four LKY compounds against nine different P450 isoforms, including CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A, in 0.25 mg/mL HLMs, under conditions common in phenotyping experiments. As shown in Table 1 , LKY-047 did not exhibit inhibitory action against the other P450 isoforms tested (IC 50 > 50 µM), whereas LKY-021, -024, and 046 showed inhibitory effects against CYP1A2,
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In conclusion, we report that (7S) 
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